Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | GLP1R | P43220 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022097 | 1.00 | MAPT (0.49) | MAPTKDM4EMEN1KMT2AHSP90AA1 | |
| SCHEMBL2022107 | 0.88 | MAPT (0.47) | MAPTKDM4EMEN1KMT2AHSP90AA1 | |
| SCHEMBL2021606 | 0.88 | MAPT (0.47) | MAPTKDM4EMEN1KMT2AHSP90AA1 | |
| SCHEMBL2019662 | 0.86 | GLP1R (0.46) | MAPTKDM4EMEN1KMT2AHSP90AA1 | |
| SCHEMBL2019148 | 0.86 | GLP1R (0.46) | MAPTKDM4EMEN1KMT2AHSP90AA1 | |
| SCHEMBL2019060 | 0.83 | TSHR (0.54) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL2018469 | 0.83 | TSHR (0.54) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL30682096 | 0.83 | TSHR (0.54) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL12574452 | 0.82 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10GLP1R | |
| SCHEMBL12574454 | 0.82 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350027-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
| CN-102143951-A | Tri-substituted pyrimidine compounds and their use as PDE10 inhibitors | MITSUBISHI TANABE PHARMA CORP | 2011-08-03 | — | — | CN | disclosed |
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| WO-2010027097-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE10A, PDE12, PDE9A | MAPT 3672/4885KDM4E 322/4885MEN1 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.